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REDUCTION OF CELL ATTACHMENT
22 x 22 mm glass coverslips were coated
with a paclitaxel-SIBS coating and placed
in cell culture media with lung cancer cells.
After 4 days, a Hoechst stain was
performed on these coverslips to visualize
the cell attachment compared to
uncoated coverslips.
PACLITAXEL CYTOXICITY
Cytotoxicity of paclitaxel was tested against lung cancer cells. However,
results of the MTT assay were inconsistent.
RELEASE KINETICS
Release kinetics of paclitaxel from the drug-eluting coating was tested
using UV-Vis spectrometry. A 1 cm2 portion of a coated stent was placed
in PBS buffer on a rocker and aliquots were taken at certain time points.
The absorbance at paclitaxel’s peak of 227 nm was recorded.
COATING STABILITY
Coating stability on the stent nitinol material was tested by placing a 2
cm2 portion of a coated stent in PBS buffer on a rocker. The weight of the
stent and coating was measured at various time points to detect coating
degradation. Results showed that the weight did not decrease over 2
weeks.
PROJECT OBJECTIVE
With 1.2 million new cases/year worldwide, lung cancer is one of the
fastest growing diseases. Patients with these malignancies in the central
airways often experience significant breathing difficulties due to
occlusion of the airways. One common palliative treatment option for this
is a stent placement procedure using the Boston Scientific
Tracheobronchial Stent (partially covered). While patients often
experience immediate symptom relief, long term use can result in the
formation of granulation tissue around the uncovered portions of the
stent causing re-occlusion of the airway.
The objective of this project is to design and prototype a modification to
the Ultraflex partially covered stent in order to reduce granulation tissue
and maintain airway patency.
DELIVERABLES
• A detailed design of stent coating and deliverable drugs
• Working prototype of pulmonary patency stent (modified Ultraflex
Tracheobronchial Stent)
• Data quantifying extent of granulation tissue reduction
DUE DILIGENCE
Drug-eluting stents have been commonly used in the coronary space.
However, paclitaxel is relatively new to airway stents. Choong et al.
(2006) showed that paclitaxel maintains patency over time in dog
airways, using a paclitaxel-eluting bypass stent meant for treating
emphysema.
Figure 2. Design for Coating on
Ultraflex Tracheobronchial Stent.
CONSIDERATIONS
• Reduce granulation tissue
• Adhesion of Coating to Stent
• Localization of Drug Response
• Controlled Release of Drug
FINAL DESIGN
Our final design consists of a paclitaxel-SIBS coating that is placed on
the uncovered ends of a Boston Scientific Ultraflex Tracheobronchial
Stent by using a dip coating method. This allows application of the
coating at the uncovered stent ends, the areas most susceptible to
granulation tissue formation.
We have shown that the SIBS-paclitaxel coating is effective in reducing
cell attachment in-vitro, the coating is stably adhered onto the stent in a
moving environment, and that paclitaxel is steadily released from the
coating. This is promising for future in-vivo testing.
Figure 5. Edge showing reduced cell 
attachment on coated side (left).
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Paclitaxel Release
Figure 8. UV-Vis absorbance of paclitaxel released over time.
Figure 4. Hoechst Stain image of 
cells on an uncoated stent piece.
Figure 6. Image J software for cell 
counting.
Figure 7. Cell Count of Coated and Uncoated 
Coverslips.
Figure 1. Granulation tissue formation at the end of an Ultraflex stent. The
lumen is occluded and the green retrieval loop is completely buried in the tissue.
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Figure 3. Coated coverslips. 
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